Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Breast Cancer Research and Treatment
|
June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
K Beelen, M Opdam, T M Severson, et al.
European Urology
|
June 4, 2023
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs
Simon Linder, Tesa M Severson, Koen J C van der Mijn, et al.
Oncotarget
|
April 30, 2016
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
Tesa M Severson, Ekaterina Nevedomskaya, Justine Peeters, et al.
Oncogene
|
May 16, 2018
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, et al.
Nucleic Acids Research
|
April 18, 2023
PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
Isabel Mayayo-Peralta, Sebastian Gregoricchio, Karianne Schuurman, et al.
NPJ Breast Cancer
|
September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR
|
August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Tesa M Severson, Denise M Wolf, Christina Yau, et al.
Molecular Oncology
|
May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
Tesa M Severson, Justine Peeters, Ian Majewski, et al.
Cancer Cell
|
November 19, 2019
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors
Parisa Mazrooei, Ken J Kron, Yanyun Zhu, et al.
Nature Communications
|
January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Ayesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Breast Cancer Research and Treatment
|
June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
K Beelen, M Opdam, T M Severson, et al.
European Urology
|
June 4, 2023
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs
Simon Linder, Tesa M Severson, Koen J C van der Mijn, et al.
Oncotarget
|
April 30, 2016
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
Tesa M Severson, Ekaterina Nevedomskaya, Justine Peeters, et al.
Oncogene
|
May 16, 2018
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, et al.
Nucleic Acids Research
|
April 18, 2023
PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
Isabel Mayayo-Peralta, Sebastian Gregoricchio, Karianne Schuurman, et al.
NPJ Breast Cancer
|
September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR
|
August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Tesa M Severson, Denise M Wolf, Christina Yau, et al.
Molecular Oncology
|
May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
Tesa M Severson, Justine Peeters, Ian Majewski, et al.
Cancer Cell
|
November 19, 2019
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors
Parisa Mazrooei, Ken J Kron, Yanyun Zhu, et al.
Nature Communications
|
January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Ayesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
Page
of 6